







Patent law has a profound effect on the status of inventors. Patents grant their right holders 
with a bundle of rights which fundamentally shape the status of inventors. EU law has had lesser 
impact on patent law compared to other fields of intellectual property (IP). There are no unitary 
patent rights within the EU as in trade marks and designs but the Unitary Patent Package (UPP) 
launched in 2012 aims at creating so-called patents with unitary effect and the creation of a 
Unified Patent court.  Areas where EU law has had effect on the status of inventors are limited 
to issues, such as biotechnological inventions, the enforcement of patent rights and the creation 
of supplementary protection measures. In addition, the EU has recently been active in the field 
of trade secrets which has ramifications for inventors. 
 
1. Introduction 
Patent rights constitute the most important regulatory measure affecting the status of 
inventors. Inventors are entitled to the grant of the patent on their invention after registration1 
providing their holders with significant economic rights.2  National patent laws of EU Member 
States have historically regulated and shaped the status of the inventor to a large extent. Some 
form of harmonisation of the substantial national patent laws within EU member states has been 
achieved outside the EU’s framework by the European Patent Convention (EPC). The EU’s 
influence on patent law has been limited when compared to trade mark and design law3 to 
certain areas of patent law, such as that in relation to biotechnological inventions. Eventually, the 
UPP which is currently being implemented may increase the EU’s involvement in the field of 
patents.  
2. The European patent system 
Patent law within EU member states which regulates the status of inventors, such as 
questions of inventor ship and employee inventions are still largely based on national law. 
However, some form of convergence of national patent laws occurred outside the EU 
framework. The most important measure is the EPC which is an intergovernmental treaty and as 
such open to non –EU Member states.4 It created the European Patent Office (EPO) which 
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provides inventors with the possibility to receive a bundle of national patents with a single 
application. The UPP may eventually provide for patent rights under the EU framework.  
2.1 Evolution of the European patent system 
The European patent system can be traced back to initiatives in the late 1940ies.5 The 
Council of Europe spearheaded these early attempts of harmonisation with the “Longchambon 
plan” which foresaw the creation of a European patent office granting European Certificates of 
Inventions. This plan can be regarded as the blueprint of the EPC of 19736 whose aim was to 
enable industry to secure patent protection across national boundaries, hence reducing cost. The 
EPC system uses a central granting office applying common rules on patentability. Once granted, 
the patent holder would enjoy protection in EPC states designated in the application.7 The 
enforcement of such patents would be subject to the applicable national law.8 The relevance of 
the EPC for harmonising patent law in Europe is increased since its substantive provisions on 
patentability have been applied in many national patent laws of EPC states. As to the 
harmonising efforts of the EU and its predecessors: Several attempts to provide for unitary 
patent rights. The first version of a Community Patent Convention 1975 (CPC1975), however, 
never came into force due to the failure of some countries to ratify it.9  Later attempts to revive 
the project, such as the CPC 1989,10 also failed.  
2.2 The Patent with unitary effect 
The current European patent framework has apparent deficiencies due to parallel 
litigation to enforce EPO bundle patents in multiple jurisdictions which increases costs and the 
possibility of national courts diverging in their findings of infringement of identical patents 
granted by the EPO.11 The CPC 1975 aimed at addressing this but would have not resolved the 
issue of adjudicating EPO patents designating non-EU states.  The European Patent Litigation 
Agreement (EPLA) elaborated under the auspices of the EPO would have allowed the 
participation of non-EU states and was favoured by many patent practitioners due to the court 
system it proposed.12 Its adoption was, however, not possible since EU member states would not 
have the competence to conclude such an agreement.13 In order to eliminate the deadlock caused 
largely due to the language regime of prospective patents of the EU,14 the Council of the EU 
authorized enhanced cooperation with respect to the creation of unitary patent protection which 
resulted in the UPP.15 Spain and Italy initially sued against the decision to apply enhanced 
collaboration but the CJEU dismissed the case.16   
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The UPP includes 3 legislative measures: 2 EU Regulations (one creating the patent with 
unitary effect17 and another on the translation regime18) and one international agreement 
between the participating Member States on a centralized court system (UPC Agreement).19 
Patents with unitary effect would be granted by the EPO.20 The court system entails a court of 
first instance with national- , regional- and a central division(s) and would oversee litigation over 
the validity and infringement of patents with unitary effect and of national European Patents of 
such EU Member States that are part of the UPP. Oddly, the substantive provisions on patent 
infringement and exceptions thereof have been placed within the Agreement on the court 
system21 and not within the Regulation where they initially were placed. This was aimed to curtail 
the CJEU’s influence on substantial patent law and is most probably based on the scepticism of 
some EU member states and practitioners towards the role of the CJEU22 on the highly technical 
subject matter of patent law. The full implementation of the Unitary Patent Package is currently 
stalled since the necessary ratifications of the UPC Agreement are lacking.23 Brexit24 and a 
Constitutional complaint before the German Federal Constitutional Court currently stall the 
ratification of the UP Agreement and the implementation of the UPP.25  
3. EU law regarding patents 
 
3.1 Biotech Directive 
The Biotech Directive26 is presently the only legislative measure by the EU that covers 
substantive patent law. It covers areas, such as patentability, the scope of protection of 
biotechnological patents, excluded subject matter and cross-licensing which makes it important 
for the status of inventors. It aims at resolving the divergent approaches towards the patenting of 
biotechnology to assist this field of technology.27 The Directive’s substantive provisions were 
adopted within the EPC framework28 in order to avoid discrepancies between the law of the 
EPC and that of EU Member States. The Directive is particularly relevant to the status of 
inventors as it enabled the patenting of genetic material by declaring biological material as being 
a patentable invention where the material is isolated from its natural environment or produced 
by means of a technical process even if it previously occurred in nature.29  
The morality exclusions within Article 6 of the Directive produced the most 
controversial case law of the CJEU in the field of patents. The patent in suit in the Brüstle case30 
involved isolated and purified neural precursor cells produced from human embryonic stem cells 
(HECSs) for treating damaged organs. The patent was challenged based on the provisions which 
declared uses of human embryos for industrial or commercial purposes as unpatentable. The 
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referring court sought the CJEU’s clarification, inter alia, on what constitutes an “embryo”. The 
CJEU provided a broad interpretation of the term embryo which would include “any human 
ovum after fertilisation.” In addition, non-fertilised human ova “into which the cell nucleus from 
a mature human cell” were transplanted or such stimulated by parthenogenesis would be 
considered as embryos. The decision was criticised31 for its wide implications for stem cell 
research in Europe, its autonomous interpretation creating a fictional consensus of what is 
considered an embryo and its questionable conformity with the TRIPS Agreement.32 In a later 
decision, the CJEU appears to have narrowed its approach with regards to non-fertilized ova.33 
But the question remained whether the CJEU, as a generalist court with the primary function of 
safeguarding the interpretation and application of EU law34, would be a suitable forum for 
adjudicating highly technical patent disputes.35  
3.2 Supplementary protection measures 
The EU’s first field of activity related to the term of protection for patents.36 The patent 
term of 20 years was deemed to be insufficient for products requiring regulatory approval, 
particularly pharmaceutical products. Before being placed on the market, medicinal and plant 
protection products require either national or EU marketing authorisation. In order to 
compensate for the delays that may occur, the European legislator provided 2 Regulations37 
which created supplementary protection certificates (SPCs) for medicinal and plant protection 
products. The recitals of the Regulations state that both product groups warrant “favourable 
rules” which would provide for sufficient protection to encourage research in Europe.38 Rather 
than extending the term of patents, the European legislator created a sui generis system distinct 
from patents in order to avoid a conflict with the maximum term of a patent of 20 years as 
stipulated in Article 63 EPC.39 SPCs take effect at the end of the term for the patent and can 
extend the effect of the basic patent for up to five years.40  
3.3 Enforcement directive 
Another field where EU law affected the status of the inventor is the enforcement of 
patents. The Enforcement Directive, which was adopted in 2004, had the aim to target 
counterfeiting and piracy, in particular actions on a large scale, industrial level.41 To address this, 
the internal market logic was applied again: Recital 9 of the Directive states that the different 
frameworks of IP enforcement would “lead to a weakening of the substantive law on intellectual 
property and to a fragmentation of the internal market in this field.” The Directive requires EU 
Member States to provide for certain enforcement measures, such as measures for preserving 
evidence, precautionary measures, injunctive relief and damages. 
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4. Trade Secrets 
Finally, a related field of law to patents influencing the statues of inventors are trade secrets. 
Inventions are often valuable information which some inventors keep secret rather than seek 
patent registration. Commercially valuable trade secrets are an important asset of many firms and 
the protection of trade secrets plays “an important role in protecting the returns to 
innovation.”42 In order to overcome the diverging approaches of trade secret protection within 
EU member states, the EU has recently adopted the Trade Secrets Directive in 2016.43 The 
Directive does not specify the role of inventors but defines the holder of a trade secret as a legal 
or natural person having control over the trade secret.44 This definition does not provide 
clarification as to the position of the inventor as the “creator,” e.g. whether he or she will be a 
joint holder of such information of the trade secret. This arguably remains to be determined by 
national laws; hence the direct impact of the Directive on the status of inventors is limited.  
5. Conclusion 
The EU has had limited direct effect on the status of inventors since national patent laws 
already forged the status of inventors to a large extent before the European legislator sought to 
regulate within this field. Where the EU legislator acted, the legislative changes were generally 
aimed at expanding the scope of protection, enhancing enforcement measures, extending the 
rights or supplementing them in form of trade secrets. These measures were based on the goal to 
eliminate distortions within the internal market. This overarching goal may have led to some 
commentators to criticise the value of the CJEU in the highly technical field of patents. In 
addition, the EU legislator is aiming at further harmonising patent law within the Union. This 
task has to resolve the complex issue of integrating the current European patent landscape. 
These activities directly affect the inventor who is also the right holder of the patent. But even 
where this is not the case, patent law and its legal reflex affect the status of inventors indirectly 
by aiming to promote innovative activities. 
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